This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Stocks in play: Microbix Biosystems Inc.
Announces the commercial usage of its first recombinant antigen product, the nucleocapsid protein of the SARS-CoV-2 virus (COVID-19), in its quality assessment products and its availability at commercial scale for test manufacturers. Microbix Biosystems Inc. shares T.MBX are trading unchanged at $0.25.
